IE
FTH

Israel Englander’s Faeth Therapeutics FTH Stock Holding History

Israel Englander’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-146,565
Closed -$4.62M – 6362
2026
Q1 		$4.62M Buy
+146,565
New +$2.93M ﹤0.01% 3036
2024
Q2 		– Sell
-1,629
Closed -$34.2K – 6487
2024
Q1 		$34.2K Sell
1,629
-286
-15% -$4.93K ﹤0.01% 5745
2023
Q4 		$26.5K Sell
1,915
-950
-33% -$13K ﹤0.01% 5591
2023
Q3 		$43K Buy
2,865
+154
+6% +$3.31K ﹤0.01% 5516
2023
Q2 		$61.8K Sell
2,711
-799
-23% -$23.4K ﹤0.01% 5434
2023
Q1 		$105K Buy
3,510
+148
+4% +$4.38K ﹤0.01% 5409
2022
Q4 		$100K Sell
3,362
-592
-15% -$17.4K ﹤0.01% 5583
2022
Q3 		$123K Sell
3,954
-2,731
-41% -$107K ﹤0.01% 5894
2022
Q2 		$304K Buy
6,685
+4,198
+169% +$157K ﹤0.01% 5346
2022
Q1 		$115K Sell
2,487
-1,878
-43% -$149K ﹤0.01% 6086
2021
Q4 		$506K Sell
4,365
-8,568
-66% -$1.28M ﹤0.01% 5033
2021
Q3 		$2.72M Buy
+12,933
New +$2.35M ﹤0.01% 3562

Other funds holding FTH

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return

Israel Englander's FTH Position: Q2 2026 in Review

Israel Englander sold out of Faeth Therapeutics (FTH) in Q2 2026, closing a stake of 146,565 shares — an estimated $4.62M sold.

Israel Englander first reported a position in FTH in Q3 2021 and held it in 12 quarters. The position peaked at $4.62M in Q1 2026. 45 funds tracked by Wall St. Rank hold FTH as of Q2 2026.

  • Israel Englander reported no remaining Faeth Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Israel Englander sold 146,565 Faeth Therapeutics shares in Q2 2026, an estimated $4.62M.
  • Israel Englander first reported a position in Faeth Therapeutics in Q3 2021 and held it in 12 quarters.
  • Israel Englander's Faeth Therapeutics position peaked at $4.62M in Q1 2026.
  • 45 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.